SMT201500235B - Formulazione comprendente derivato di fenilamminopirimidina come agente attivo - Google Patents

Formulazione comprendente derivato di fenilamminopirimidina come agente attivo

Info

Publication number
SMT201500235B
SMT201500235B SM201500235T SM201500235T SMT201500235B SM T201500235 B SMT201500235 B SM T201500235B SM 201500235 T SM201500235 T SM 201500235T SM 201500235 T SM201500235 T SM 201500235T SM T201500235 B SMT201500235 B SM T201500235B
Authority
SM
San Marino
Prior art keywords
formulation
active agent
phenylaminopyrimidine derivative
phenylaminopyrimidine
derivative
Prior art date
Application number
SM201500235T
Other languages
English (en)
Italian (it)
Inventor
Durga Maheswari Parvataneni
Siddhartha Yedluri
Venkata Satyanarayana Appadwedula
Kali Satya Bhujanga Rao Adibhatla
Venkaiah Chowdary Nannapaneni
Original Assignee
Natco Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43923331&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201500235(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Natco Pharma Ltd filed Critical Natco Pharma Ltd
Publication of SMT201500235B publication Critical patent/SMT201500235B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
SM201500235T 2011-03-07 2015-09-29 Formulazione comprendente derivato di fenilamminopirimidina come agente attivo SMT201500235B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1103860.1A GB2488788B (en) 2011-03-07 2011-03-07 Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response
PCT/IB2011/001842 WO2012120328A1 (en) 2011-03-07 2011-08-10 Formulation comprising phenylaminopyrimidine derivative as active agent

Publications (1)

Publication Number Publication Date
SMT201500235B true SMT201500235B (it) 2015-10-30

Family

ID=43923331

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201500235T SMT201500235B (it) 2011-03-07 2015-09-29 Formulazione comprendente derivato di fenilamminopirimidina come agente attivo

Country Status (33)

Country Link
US (1) US9895367B2 (enExample)
EP (1) EP2683381B1 (enExample)
JP (1) JP5788534B2 (enExample)
KR (1) KR101767296B1 (enExample)
CN (1) CN103561742B (enExample)
AP (1) AP4076A (enExample)
AU (1) AU2011361921B2 (enExample)
BR (1) BR112013022930A2 (enExample)
CA (1) CA2829015C (enExample)
CO (1) CO6811851A2 (enExample)
CY (1) CY1116968T1 (enExample)
DK (1) DK2683381T3 (enExample)
EA (1) EA024610B1 (enExample)
ES (1) ES2554927T3 (enExample)
GB (1) GB2488788B (enExample)
GE (1) GEP20156410B (enExample)
HR (1) HRP20151382T1 (enExample)
HU (1) HUE025562T2 (enExample)
IL (1) IL228218A (enExample)
MA (1) MA35088B1 (enExample)
MX (1) MX339130B (enExample)
MY (1) MY158693A (enExample)
NZ (1) NZ614903A (enExample)
PH (1) PH12013501844A1 (enExample)
PL (1) PL2683381T3 (enExample)
PT (1) PT2683381E (enExample)
RS (1) RS54420B1 (enExample)
SG (1) SG193349A1 (enExample)
SI (1) SI2683381T1 (enExample)
SM (1) SMT201500235B (enExample)
UA (1) UA111074C2 (enExample)
WO (1) WO2012120328A1 (enExample)
ZA (1) ZA201306643B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6896738B2 (ja) 2015-12-18 2021-06-30 ナトコ ファーマ リミテッド フェニルアミノピリミジン誘導体を含む医薬組成物
WO2017115316A1 (en) * 2015-12-29 2017-07-06 Noivita S.R.L.S. Lipophilic formulations
CN107184549B (zh) * 2017-04-11 2020-11-20 江苏大学 一种尼达尼布自微乳制剂和其制成的软胶囊及制备方法
CN107564610A (zh) * 2017-10-20 2018-01-09 浙江中大元通特种电缆有限公司 一种陶瓷化硅橡胶绝缘护套不锈钢连锁铠装防火电缆
RS65257B1 (sr) 2018-03-14 2024-03-29 Kandy Therapeutics Ltd Nova farmaceutska formulacija koja sadrži dvojne antagoniste receptora nk-1/nk-3
CN113473974A (zh) * 2019-01-25 2021-10-01 深圳市药欣生物科技有限公司 药物组合物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
KR100509776B1 (ko) * 1997-07-29 2005-08-24 파마시아 앤드 업존 캄파니 엘엘씨 친지성 화합물의 자가유화 제제
US6248354B1 (en) * 1999-03-04 2001-06-19 Allergan Sales, Inc. Capsule system
US7232825B2 (en) * 2003-05-02 2007-06-19 Guoqing P Chen Phenylaminopyrimidine derivatives and methods of use
EP1498143A1 (en) * 2003-07-18 2005-01-19 Aventis Pharma S.A. Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids
HRP20070146B1 (hr) * 2004-09-09 2015-12-04 Natco Pharma Limited Novi derivati fenilaminopiridina kao inhibitori bcr-abl kinaze
US20080207904A1 (en) * 2006-10-26 2008-08-28 Macdonald Peter Imatinib base, and imatinib mesylate and processes for preparation thereof
EP1920767A1 (en) * 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
EP2073850B1 (en) * 2007-04-30 2010-10-27 Intezyne Technologies Inc. Hybrid block copolymer micelles with mixed stereochemistry for encapsulation of hydrophobic agents
KR20100126464A (ko) * 2008-03-04 2010-12-01 낫코 파마 리미티드 페닐아미노 피리미딘 유도체의 결정 형태
US8067422B2 (en) 2008-03-04 2011-11-29 Natco Pharma Limited Crystal form of phenylamino pyrimidine derivatives
JP5791500B2 (ja) * 2008-05-23 2015-10-07 パンミラ ファーマシューティカルズ,エルエルシー. 5−リポキシゲナーゼ活性化タンパク質阻害剤

Also Published As

Publication number Publication date
IL228218A (en) 2016-06-30
CN103561742A (zh) 2014-02-05
ZA201306643B (en) 2014-11-26
DK2683381T3 (en) 2015-12-21
GB2488788A (en) 2012-09-12
SI2683381T1 (sl) 2016-01-29
AP2013007128A0 (en) 2013-09-30
BR112013022930A2 (pt) 2016-12-06
EA201391280A1 (ru) 2014-02-28
NZ614903A (en) 2014-08-29
CY1116968T1 (el) 2017-04-05
WO2012120328A1 (en) 2012-09-13
JP2014507463A (ja) 2014-03-27
PL2683381T3 (pl) 2016-06-30
RS54420B1 (sr) 2016-04-28
MA35088B1 (fr) 2014-05-02
AP4076A (en) 2017-03-23
GEP20156410B (en) 2015-12-10
KR101767296B1 (ko) 2017-08-10
PH12013501844A1 (en) 2015-10-23
MX339130B (es) 2016-05-13
KR20140016926A (ko) 2014-02-10
AU2011361921A1 (en) 2013-09-26
SG193349A1 (en) 2013-10-30
MX2013010160A (es) 2013-12-06
HRP20151382T1 (hr) 2016-02-12
US20130338180A1 (en) 2013-12-19
GB201103860D0 (en) 2011-04-20
ES2554927T3 (es) 2015-12-28
EA024610B1 (ru) 2016-10-31
CO6811851A2 (es) 2013-12-16
US9895367B2 (en) 2018-02-20
MY158693A (en) 2016-11-15
CA2829015A1 (en) 2012-09-13
GB2488788B (en) 2013-07-10
JP5788534B2 (ja) 2015-09-30
UA111074C2 (uk) 2016-03-25
EP2683381B1 (en) 2015-09-16
AU2011361921B2 (en) 2016-06-09
AU2011361921A2 (en) 2014-10-30
EP2683381A1 (en) 2014-01-15
PT2683381E (pt) 2015-11-02
HUE025562T2 (en) 2016-03-29
CA2829015C (en) 2018-01-02
CN103561742B (zh) 2016-04-27

Similar Documents

Publication Publication Date Title
PT2755473T (pt) Composições parasiticidas compreendendo um agente ativo de isoxazolina, métodos e suas utilizações
PT3061454T (pt) Composições veterinárias orais parasiticidas compreendendo agentes activos de actuação sistémica, métodos e as suas utilizações
BR112013013311A2 (pt) agente terapêutico de indução de citotoxicidade
BR112014009634A2 (pt) preparação e agente terapêutico
SMT201800332T1 (it) Agente antincendio autonomo
CO6811868A2 (es) Combinaciones de principios activos
EP2611310A4 (en) ANTIMICROBIAL FORMULATION
BR112014012005A2 (pt) composições, métodos, formulação farmacêutica e artigo
EP2758052A4 (en) PHARMACEUTICAL COMPOSITIONS
EP2783709A4 (en) SUBMUCOSIVE DAMPER
DK2900645T3 (da) Herbicidt aktive 3-phenylisoxazolinderivater
CR20140068A (es) Una formulación herbicida mejorada
BR112014000015A2 (pt) formulação
CO6852077A2 (es) Composiciónes que comprenden ditiínas sustituidas fungicidas y compuestos activos adicionales
SMT201500320B (it) Liofilizzazione di agente tensioattivo polmonare liposomale sintetico
CO6940426A2 (es) Formulaciones farmacéuticas
DK2868318T4 (da) Injicerbar formulering
PT2773197T (pt) Composição de ionómero antimicrobiana e as suas utilizações
SMT201500235B (it) Formulazione comprendente derivato di fenilamminopirimidina come agente attivo
PL2836580T3 (pl) Mikrofibrylarna celuloza jako substancja czynna zdolna do odrywania brudu
IL229081A0 (en) Isoxazolines as therapeutic agents
ITRE20110042A1 (it) Agente sanitario
HUE050945T2 (hu) Gyógyszerforma hatóanyagok nyújtott felszabadítására
BR112013024082A2 (pt) composições de agente branqueador fluorescente
PL2908835T3 (pl) Stabilne formulacje